Sepsis represents a significant public health challenge, marked by elevated morbidity, high mortality rates, and substantial economic strain. As emerging technologies continue to evolve, there is a positive anticipation that diagnostic methods and rates for sepsis will witness significant improvement in China. Against this backdrop, China’s incidence of diagnosed sepsis cases is expected to grow at a compound annual growth rate of around 2% between 2023 and 2033, forecasts GlobalData, a leading data and analytics company.

GlobalData’s research reveals that the incident cases of diagnosed sepsis in China will surpass 4 million in 2029 due to multifaceted reasons including the development and integration of innovative diagnostic solutions that are likely to contribute to more accurate and timely identification of sepsis cases.

Fapon Biotech Inc has recently forged a strategic cooperation agreement with two Swiss biotech companies, LASCCO SA and Abionic SA, for an exclusive license to employ the pancreatic stone protein (PSP) biomarker for sepsis diagnosis. This strategic collaboration represents a major advancement in early diagnosis of sepsis.

Shreya Jain, Medical Devices Analyst at GlobalData, comments: “Timely diagnosis and early therapeutic intervention are crucial factors determining clinical outcomes in sepsis. However, early diagnosis of sepsis is marked by several challenges owing to the non-specific symptoms and coexisting conditions. Furthermore, the conventional detection methods frequently fall short, as they lack the required precision.”

With a goal to enhance early sepsis screening, expand clinical applications, and provide faster and more effective solutions for septic patients in China, Fapon will expedite the introduction of PSP raw materials and reagent solutions for chemiluminescence immunoassay platforms to the market.

Given the reliability of PSP as an early marker of sepsis, the PSP immunoassay has secured CE mark approval under the In Vitro Diagnostic Medical Devices regulations, Australian registration and FDA 510(k) clearance is expected in 2024.

Jain concludes: “The importance of early sepsis detection extends beyond improving survival rates; it also encompasses the crucial goal of minimizing the risk of severe complications. Thus, an urgent requirement exists for the integration of novel technologies and advancements that have the potential to improve the precision and accessibility in the field of sepsis detection and management.”